A PCR-based microwell-plate hybrid capture assay for high-risk human papillomavirus by Yumei Wang et al.
BRIEF REPORT
A PCR-based microwell-plate hybrid capture assay for high-risk
human papillomavirus
Yumei Wang • Yan Liu • Yaping Ding •
Nan Sun • Yafang Gong • Shangxian Gao
Received: 28 February 2014 / Accepted: 17 July 2014 / Published online: 5 August 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Human papillomavirus (HPV) is associated
with cervical cancer. In this study, we developed a high-
throughput microwell-plate hybrid capture (MPHC)
method for epidemiological studies of high-risk HPV
(HRHPV). The results with 1238 cervical specimens from
female outpatients showed a concordance rate of 94.3 %
between the MPHC and Hybrid Capture II assay. The
MPHC assay showed an average HRHPV rate of 29.3 %
for high-risk populations in populous cities of China. The
established MPHC assay could sensitively and specifically
detect 13 types of HRHPV and is suitable for large-scale
screening, especially in areas where real-time PCR or
fluorescence equipment is unavailable.
It is well established that persistent infection with high-risk
human papillomaviruses (HPV) plays the leading etiolog-
ical role in the development of cervical and anal cancer and
their immediate precursors [1–3]. Based on sequence
differences within their L1 gene, HPVs are divided into
more than 100 different genotypes, in which approximately
40 types of HPV transmitted through the genital tract have
been classified further as ‘‘low-risk’’ and ‘‘high-risk’’ based
on their association with malignant lesions [4]. The
worldwide prevalence of high-risk human papillomavirus
(HRHPV) infection in women without cervical abnormal-
ities ranges from 0 to 48.4 %, and in developing countries,
such as the countries of Asia and sub-Saharan Africa, the
prevalence is higher than that in developed countries [5–7].
China is currently estimated to have 130,000 new cervical
cancer cases each year, accounting for 28 % of the world’s
total [8]. Therefore, a high-throughput assay is urgently
needed for assessing the level of the HRHPV epidemic in
current populations for the diagnosis and treatment of
cervical cancer [9–11].
Several HPV detection methods, including PCR-based
methods and the Hybrid Capture II-based system, have
been established to assess the presence of 13 high-risk
HRHPVs [12–14]. In these methods, several consensus or
degenerate primer pairs have been designed to amplify the
relatively conserved region of the L1 gene in the HPV
genome, including GP5/GP6 and PGMY09/PGMY11 [15,
16]. Although these consensus or degenerate primers could
amplify a wide spectrum of HPV genotypes, the sensitivity
and specificity of different primer sets to detect HPV DNA
need to be evaluated in a clinical study, and the overall
prevalence of HPV needs to be properly estimated by a
variety of detection methods [16, 17]. Moreover, neither
cytology-based screening nor molecular tests for HRHPV
are widely available in developing countries, which lack
the necessary human, financial, and material resources,
including instruments such as real-time PCR equipment
and fluorescence detectors. Therefore, it is essential to
develop a low-cost, high-throughput screening method to
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test large numbers of patients in developing countries [18].
In this paper, we describe a sensitive, low-cost, high-
throughput and easily operated microwell-plate hybrid
capture (MPHC) assay that detects 13 HRHPV types using
a novel set of primers that specifically bind to the L1
region.
For the MPHC system, the YR8/YR10 primer set was
used, which contains eight forward primers and nine
reverse primers. Both primer pools were conjugated with
biotin at their 50 ends. Two segments of the amplified
sequence, one each from the sense and antisense strands,
were selected as the capture probes. Each probe had an
oligo-T linker modified with an amino group at its 50 end.
The sequences of all the primers and the probes and their
GenBank accession numbers are shown in Table 1.
Twenty-six HPV probe mixtures were immobilized to
activated microwells. Compared with the PGMY11/
PGMY09 consensus primer set, which produces a product
of 450 bp [16], the YR8/YR10 primer set produces a
shorter product of 185 bp, which reduces the spatial
obstacles to hybridization, thus improving the overall
efficiency of hybridization.
For the establishment and validation of the MPHC assay,
the HPV DNA was amplified with the YR8/YR10 primer set
and the biotin-conjugated products were added to the probe-
coated microwells. After alkaline denaturation, neutraliza-
tion, hybridization and washing, horseradish-peroxidase-
conjugated streptavidin (Dako) was used to bind target PCR
products, and 30,30,5,50-tetramethylbenzidine (Sigma-
Aldrich) was then used to develop the color reaction. The
optical density at 450 nm (OD450) of each well was measured
using an enzyme-linked immunosorbent assay plate reader
(SpectraMax M5).
The negative and positive cutoff values for the MPHC
method were first estimated from 400 samples that were
identified as negative by calculating the mean negative
OD450 values plus two or three standard deviations to be
0.56 and 0.70, respectively (Fig. 1A). The cutoff values
were then validated with another 100 specimens identi-
fied with the HCII assay (50 % negative and 50 %
positive). It was found that the OD450 values of more
than 95 % of the negative samples were lower than 0.56,
and more than 95 % of the positive samples had values
higher than 0.70 (Fig. 1B). Therefore, the equivocal zone
was between 0.56 and 0.70. Ambiguous specimens were
tested again in duplicate and were defined as positive
when one result was positive or two results were
equivocal in these duplicate reactions. Otherwise, when
the value of a specimen that is suspected to be infectious
is in the range of 0.70–1.0, we suggest that a second
specimen be analyzed and/or an alternative testing
method be used, especially for liquid-preserved cytology
specimens.
In order to determine the sensitivity and specificity of
MPHC, 43 types of HPV (types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68, 6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57,
62, 64, 66, 67, 69, 70, 71, 72, 73, 79, 80, 81, 82, 83, 84, 87, 90,
and 91) plasmids were constructed. The sequence informa-
tion for the HPVs was obtained from the GenBank database.
To determine the detection limits of the MPHC for HPV
DNA, a serial 10-fold dilution of each HRHPV plasmid and
human genomic DNA from HPV18-transformed cells (PZ-
HPV-7, ATCC CRL-2221D) was tested and analyzed using
the MPHC assay to determine the positive cutoff concentra-
tion. To further determine the specificity of the assay, the
assay was tested against DNA from viral strains, bacterial
cultures, and clinical samples, including cytomegalovirus,
herpes simplex virus 2, Chlamydia trachomatis, Ureaplasma
urealyticum, Neisseria gonorrhoeae, Mycoplasma humenis,
M. genitalium, E. coli, Bacillus pyocyaneus, Staphylococcus
aureus, Candida albicans, and Treponema pallidum. The
results showed that all 13 HRHPV plasmids were detected as
positive at concentrations of 103 copies/lL to 105 copies/lL.
At a concentration of 100 copies/lL, the OD values were
close to the cutoff value for type 31 and type 52 and were
0.5–1.0 for type 56, but at a concentration of 500 copies/lL,
they showed positive results. Only six types of plasmid (types
16, 18, 35, 45, 58, and 59) were positive at a concentration of
10 copies/lL (Fig. 2). At the concentration of 104–105 cop-
ies/lL, no positive results were obtained by the MPHC
method for any of the non-HRHPV or other common genital-
tract pathogens, indicating a lack of cross-reactivity between
the high-risk and low-risk or genital-tract pathogens. It is
believed that the specificity of the screen is determined only
by the specificity of the probes. HPV18-transformed cells
were used to compare the differences in the MPHC assay
results when cells expressing virus or plasmids were ana-
lyzed. Although the sensitivity in detecting type 18 HRHPV
was the same for the two samples, the HPV18-transformed
cell based method was not suitable for evaluation of the dif-
ferences in the primer and probe sequences between different
HPV types.
To determine the epidemic levels of the 13 HRHPV
types in high-risk populations in populous cities of China,
1238 cervical specimens were collected as described by the
manufacturer of the HCII High-Risk HPV DNA test kit
(Digene) [19] and detected by the MPHC and HCII
method, respectively. The HCII test was performed with
the automated HCII system as described previously [19].
Of the 1238 samples tested, 306 (25 %) were HRHPV
positive and 862 (70 %) were HRHPV negative when
measured by both methods. The two methods had a high
concordance rate of 94.3 %. A kappa analysis showed a
score of 0.859 (SPSS, ver. 18.0, IBM), indicating an
‘‘almost perfect’’ match between these two assays. How-
ever, the results for 70 (6 %) samples were discordant
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Table 1 Primers and probes used for the MPHC assay of HRHPV
Primer/probe Name Sequence (50–30) Accession number and nucleotide
position
Forward primer YR8-A Bio-GCACAGGGTCATAATAATGGTATTTGTTGG gb|FJ202006.1|: bp4-33
YR8-B Bio- GCACAGGGACATAATAATGGCATTTGCTGG gb|U12488.1|: bp1-30
YR8-C Bio-GCACAGGGCCACAATAATGGTATTTGTTGG dbj|AB889493.1|: bp6587-6616
YR8-D Bio-GCACAGGGTCATAACAATGGTATTTGCTGG gb|KF225496.1|: bp149-178
YR8-E Bio-GCTCAGGGTTTAAACAATGGTATATGTTGG gb|KC470266.1|: bp6551-6182
YR8-F Bio-GCCCAGGGCCACAACAATGGTATATGTTGG gb|KC470239.1|: bp6612-6641
YR8-G Bio-GCCCAGGGACATAATAATGGCATTTGTT emb|AJ620205.1|: bp6696-7 = 6723
YR8-H Bio- GCACAGGGTCATAACAATGGTATCTGCTGG gb|KC470221.1|: bp6532-6561
Reverse primer YR10-A Bio-TGAAAAATAAACTGTAAATCATATTCCTC dbj|AB889494.1|: bp6767-6739
YR10-B Bio-TGAAAAATAAACTGTAAATCATATTCTTC gb|KC991279.1|: bp146-118
YR10-C Bio-TGAAAAATAAACTGTAAATCATACTCTTC gb|EF202168.1|: bp6626-6598
YR10-D Bio-TGAAAAATAAACTGTAAATCAAACTCCTC gb|KC815977.1|: bp182-154
YR10-E Bio-TGAAAAATAAACTGTAAATCAAATTCCTC gb|GQ396222.1|: bp72-44
YR10-F Bio-TGAAAAATAAACTGTAAATCATACTCCTC gb|EU056622.1|: bp48-20
YR10-G Bio-TGAAAAATAAATTGTAAATCATACTCTTC emb|HE805662.1|: bp124-96
YR10-H Bio-TGAAAAATAAATTGCAAATCATATTCTTC gb|KC792556.1|: bp1133-1105
YR10-I Bio- TGAAAAATAAACTGTATGTCATATTCTTC gb|JQ041819.1|: bp158-130
Probes for
HPV16
Probe-16F amine - TTTTTTTTTTTTTTTTAAGGAGTACCTACGACATGG dbj|AB889494.1|: bp6718-6737
Probe-16R amine - TTTTTTTTTTTTTTTGATATGGCAGCACATAATGAC dbj|AB889494.1|: bp6683-6663
Probes for
HPV18
Probe-18F amine - TTTTTTTTTTTTTTTTGCTTCTACACAGTCTCCTGTA gb|KF225496.1|: bp239-259
Probe-18R amine - TTTTTTTTTTTTTTTCTTAAATTTGGTAGC ATCATATTG gb|KF225496.1|: bp289-266
Probes for
HPV31
Probe-31F amine - TTTTTTTTTTTTTTTCCA CTCCATTTA AACCATCTG gb|KC991270.1|:bp36-54
Probe-31R amine - TTTTTTTTTTTTTTTCGCCATGTCTTATAAATTGTT gb|KC991270.1|: bp89-70
Probes for
HPV33
Probe-33F amine - TTTTTTTTTTTTTTTAT ATATAAGACATGTTGAAGAA gb|KC706450.1|: bp265-244
Probe-33R amine - TTTTTTTTTTTTTTTCTGTCACTAGTTACTTGTGTGCAT gb|KC706450.1|: bp293-361
Probes for
HPV35
Probe-35F amine - TTTTTTTTTTTTTTTCTGCTGTGTCTTCTAGTGACAG gb|KC991278.1|: bp53-74
Probe-35R amine - TTTTTTTTTTTTTTTCACAGACATATTTGTACTACGGG gb|KC991278.1|: bp48-26
Probes for
HPV39
Probe-39F amine - TTTTTTTTTTTTTTTTAGAGTCTTCCATACCTTCTAC gb|KC470249.1|:bp6683-6703
Probe-39R amine - TTTTTTTTTTTTTTTGCCTGGTATATTCCTTAAACTTA gb|KC470249.1|:bp6738-6716
Probes for
HPV45
Probe 45F amine - TTTTTTTTTTTTTTTTGACCCTACTAAGTTTAAGCAG gb|KC470256.1|: bp6676-6697
Probe-45R amine - TTTTTTTTTTTTTTTGCACAGGATTTTGTGTAGAG gb|KC470256.1|: bp6665-6646
Probes for
HPV51
Probe-51F amine - TTTTTTTTTTTTTTTTATTAGCACTGCCACTGCTG gb|S40272.1|: bp16-36
Probe-51R amine - TTTTTTTTTTTTTTTCTTGGAGTAAATGTTGGGG gb|S40272.1|: bp77-54
Probes for
HPV52
Probe-52F amine - TTTTTTTTTTTTTTTGGAATACCTTCGTCATGG gb|KF225497.1|: bp987-1009
Probe-52R amine - TTTTTTTTTTTTTTTCCTTTTTAACCTCAGCAC gb|KF225497.1|: bp1040-1018
Probes for
HPV56
Probe-56F amine - TTTTTTTTTTTTTTTTGACTATTAGTACTGCTACAGAA gb|KC815983.1|: bp75-96
Probe-56R amine - TTTTTTTTTTTTTTTCG TGCATCATATTTACTTAACTG gb|KC815983.1|: bp119-97
Probes for
HPV58
Probe-58F amine - TTTTTTTTTTTTTTGACATTATGCACTGAAGTAACTAAG dbj|AB819279.1|: bp6668-6692
Probe-58R amine - TTTTTTTTTTTTTTTCATATTCCTTAAAATTATCATT dbj|AB819279.1|: bp6729-6708
Probes for
HPV59
Probe-59F amine - TTTTTTTTTTTTTTTCCTAATGTATACACACCTACCAG gb|KC470266.1|: bp6662-6684
Probe-59R amine - TTTTTTTTTTTTTTTAGAAGAAGTAGTAGAAGCACA gb|KC470266.1|: bp6658-6638
Probes for
HPV68
Probe-68F amine - TTTTTTTTTTTTTTTCTACTACTGAATCAGCTGTACC gb|KC470283.1|: bp6544-6565
Probe-68R amine - TTTTTTTTTTTTTTTCCTTAAATTTATTAGGATCATA gb|KC470283.1|:bp6594-6573
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between the two assays. To confirm the type of virus
present in the specimens with discordant results in HCII
and MPHC, the samples were subjected to DNA
sequencing, which showed that MPHC was correct for 33
samples, and HCII was correct for 6 samples. Twenty-
seven specimens produced no HPV sequence results, and
these were assumed to be HPV negative.
Based on these results, the sensitivity and specificity of
the MPHC assay were 98.5 % (339/344) and 97.3 % (870/
894), respectively. The HRHPV prevalence rate, when
measured by MPHC, was 29.3 % (363/1238) in cervical
specimens sampled from hospitals in three different
regions of China. Although DNA sequencing is regarded as
the gold-standard technique, there were still false negatives
for the 24 samples diagnosed as positive by MPHC but
negative by HCII assay (HCII–MPHC?), which were
deemed to be negative based on sequencing failure, even if
their MPHC detection values were more than 1.5. Because
most sequencing failures are caused by the condition of the
sample, including too little DNA, the 29.3 % positive
detection rate with the MPHC method, which was higher
than that with the HCII method, may be closer to the true
positive rate. Therefore, the prevalence of HRHPV infec-
tion in female outpatients was between 27.8 % and 29.3 %
in the regions of China examined, which was higher than
those in the report by Li et al. [7].
The most prevalent HPV screening method is the HCII
assay, which has been approved by the U.S. FDA. This
method is validated by the strong agreement between its
results and those of cytological or histological assays [20,
21]. However, the high cost of the assay makes it unfea-
sible for the routine mass screening of cervical infections in
Fig. 1 Determining the negative and positive cutoff values. A)
Estimation of the cutoff value with 400 samples negative for HRHPV.
The negative and positive cutoff values were estimated by calculating
the mean negative OD450 values plus two or three standard deviations
to be 0.56 and 0.70, respectively. B) Validation of the cutoff levels by
MPHC assays performed on samples classified as negative or positive
by the HCII assay. Using the cutoff value derived from the analysis
described above as the criterion for positive specimens, more than
95 % of samples were identified as positive. The positive samples in
the negative region were verified by DNA sequencing analysis and
resolved as positive. This scatter plot was constructed with GraphPad
Prism 5.0 (GraphPad Software, San Diego, CA, USA)
Fig. 2 Detection limit of the MPHC assay for each of the 13 HRHPV
plasmids at concentrations ranging from 10 copies/lL to 105 copies/
lL. The symbol (O) shows the OD450 value. The dotted line
represents the positive cutoff value, estimated to be 0.7. Each data
point represents the average of three duplicated experiments
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resource-poor areas of developing countries [22]. The
present study suggested that the MPHC method is similar
to HCII in terms of its specificity and sensitivity. In this
study, using the same collection method, we eliminated the
effects of the sample collection method. Therefore, the
comparative results reflect the true efficiency of the PCR
amplification, hybridization, and signal development
achieved with the two methods.
A previous study revealed false positive results with the
HCII method in detecting these 13 HRHPV types when 1
RLU/CO (relative light unit) was used as the cutoff value
[23, 24]. The most frequently detected false positives
occurred with HRHPV types 53, 66, 67, and 73 [25]. In this
study, three of the five HCII-positive but MPHC-negative
(HCII?MPHC-) samples were confirmed by sequencing to
be true negatives, and they belonged to type 66, whereas
the other two samples belonged to type 73. In the same
analysis, three of the five HCII?MPHC- samples were
confirmed by sequencing to be true positives and belonging
to type 52, whereas the other two samples were types 33
and 35. The sequencing results showed that the HPV types
of the HCII–MPHC? samples were limited to HPV types
16 (12/33), 58 (7/33), 59 (7/33), 35 (3/33), 45 (3/33) and 18
(1/33). These results suggested that the MPHC method was
more sensitive than HCII in detecting HPV types 16, 35,
45, 58, and 59, and that the detection efficiency for type 52
requires further improvement. The MPHC assay for plas-
mids was slightly less sensitive in detecting three HPV
types (types 31, 52, and 56) than in detecting the other
types tested. The OD values at plasmid concentrations of
100 copies/lL were close to the cutoff value for type 31
and type 52 and were in the range of 0.5–1.0 for type 56.
Therefore, their unstable concentration was 100 copies/lL.
Despite finding no false-negative type 31 or type 56 HPV
in the clinical samples (although we did find false-negative
type 52), we must increase the sensitivity of their detection
in this assay.
In summary, a sensitive, specific, low-cost, high-
throughput PCR-based method was developed to detect 13
types of HRHPV in patient specimens. Although this
hybridization process takes more time than the real-time
PCR assay, it is a sensitive and specific assay that should
enhance the study of HRHPV infections and the prevention
of cervical cancer among a larger population. However,
much effort should be made to standardize the established
MPHC before it is widely applied clinically.
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